Targeted anti-cancer combination therapy with infusion of N-acetyl-L-methionine (NALM) and N-acetyl-L-selenomethionine (NASeLM) shows promising results in cancer treatment. Selenium has been recognised as a valuable additive in cancer therapeutics due to its ability to minimise side effects of chemotherapy and its role in cancer prevention and therapy. Due to the promising results of this new therapeutic approach evaluation of pharmacokinetic data for NALM and NASeLM is of ultimate importance.
View Article and Find Full Text PDF